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Background: In malaria-endemic countries, large proportions of infected individuals are asymptomatic, constituting
a reservoir of parasites for infection of newly hatched mosquitoes. This study evaluated the impact of screening
and treatment of asymptomatic carriers of Plasmodium falciparum.
Methods: Eighteen villages were randomized (1:1) to study arms and inhabitants participated in four community
screening campaigns: three before the rainy season ~1 month apart, and the fourth after the rains at ~12 months.
On day 1 of campaigns 1–3, asymptomatic carriers in the intervention arm were identified by rapid diagnostic test
and treated with artemether-lumefantrine. Outcomes were symptomatic malaria with parasite density >5,000/μL per
person-year in children <5 years and change in haemoglobin between days 1 and 28 of campaign 1.
Results: At 12 months, the number of symptomatic malaria episodes with a parasite density >5,000/μL per person-
year in children <5 years was not significantly different between arms (1.69 vs 1.60, p = 0.3482). Mean haemoglobin
change in asymptomatic carriers during campaign 1 was greater in the intervention vs control arm (+0.53 g/dL vs
-0.21 g/dL, p <0.0001). ANCOVA demonstrated that mean asymptomatic carriage at the cluster level was lower in
the intervention vs control arm at day 1 of campaigns 2 (5.0% vs 34.9%, p <0.0001) and 3 (3.5% vs 31.5%, p <0.0001),
but showed only a small difference at day 1 of campaign 4 (34.6% vs 37.6%, p = 0.2982). Mean gametocyte carriage
was lower in the intervention vs control arm at day 1 of campaigns 2 and 3 (0.7% vs 5.4%, p <0.0001; 0.5% vs 5.8%,
p <0.0001), but was similar at day 1 of campaign 4 (4.9% vs 5.1%, p = 0.7208).
Conclusions: Systematic screening and treatment of asymptomatic carriers at the community level did not reduce
clinical malaria incidence in the subsequent transmission season, indicating greater levels of parasite clearance are
required to achieve a sustained impact in this setting.
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In malaria-endemic countries, a large proportion of
Plasmodium falciparum infections are asymptomatic.
Microscopy-detected levels of asymptomatic carriage as
high as 39% have been reported [1-3] but the exact role of
asymptomatic carriers in the dynamics and transmission
of malaria is currently unclear [4]. However, as they do
not seek treatment for their infection, asymptomatic
carriers can have high levels of gametocytes [1] and con-
stitute an important parasite reservoir available for infec-
tion of newly hatched mosquitoes [4,5]. Even in areas of
highly seasonal malaria transmission, studies have shown
that a considerable proportion of the population remain
positive for parasitaemia throughout the year [1,3]. In
addition to constituting a parasite reservoir responsible
for malaria transmission, individuals with asymptomatic
parasitaemia are at risk of developing anaemia and may
progress to symptomatic malaria.
The systematic identification and treatment of asymp-
tomatic carriers could potentially reduce disease transmis-
sion by reducing the pool of parasites carried by these
individuals. This hypothesis is supported by a modelling
and simulation analysis that evaluated the impact of com-
munity screening campaigns followed by treatment of
asymptomatic carriers with artemether-lumefantrine (AL)
(CoartemW, Novartis Pharma AG, Basel, Switzerland) [6].
This simulation suggested campaign visits placed in close
succession in the period prior to the malaria transmission
season should effectively clear asymptomatic infection
from communities and significantly reduce the subsequent
incidence of disease in those communities [6]. Similar
predictions were obtained by Okell et al. in their model-
ling of the impact of two mass treatment strategies [7].
AL has demonstrated consistently high efficacy and
safety for over a decade and is included on the WHO
Model List of Essential Medicines [8,9]. For the interven-
tion to be effective, a large proportion of asymptomatic
carriers in a defined district need to receive treatment to
significantly reduce the reservoir of parasites in that com-
munity. For this reason the unit of randomization and
analysis used in this study was the village. This study,
therefore, evaluated the impact on malaria incidence of
community-level screening (using RDT) and treatment of
asymptomatic carriers of P. falciparum on the number of
microscopy-confirmed cases of symptomatic malaria with
a parasite density >5,000/μL seen over a 12-month period,
compared with no screening with RDT nor treatment of
asymptomatic carriers, as well as the direct benefit from
treatment on haemoglobin (Hb) levels in asymptomatic
carriers who received AL. Subjects in both the interven-
tion and control arms had blood smears taken for delayed
microscopy reading. The parasite density requirement was
used to avoid a potential anti-conservative bias. If febrile
patients with lower levels of parasitaemia were included inthe analysis, then participants in the control arm with
non-malarial fever might incorrectly be counted as symp-
tomatic malaria cases, making the intervention appear
more effective. Data showed systematic screening and
treatment of asymptomatic carriers in this setting did not
reduce clinical malaria incidence in the subsequent trans-
mission season, possibly indicating greater levels of para-
site clearance are required to achieve a sustained impact.
Hb levels were, however, improved with the intervention.
Methods
Study population
The study took place in the health district of Saponé,
about 50 km south of Ouagadougou in Burkina Faso,
which is an area with marked seasonal malaria transmis-
sion of P. falciparum from June to November [10]. All
clusters considered for selection were part of a demo-
graphic surveillance system that routinely monitors the
vital events occurring within these villages (e.g., births,
deaths, in/out migration). All inhabitants of each cluster
were invited to participate in the trial. Written informed
consent was obtained from all study participants or their
legal guardians.
Study design
This study was a single-centre, controlled, parallel, cluster-
randomized study to evaluate the effect of systematic
treatment of P. falciparum asymptomatic carriage at a
community level on the number of symptomatic malaria
episodes, with a parasite density >5,000/μL per person-
year in children <5 years of age over a 12-month period
compared with no treatment of asymptomatic carriers.
Eighteen clusters, each comprised of one village, reporting
to eight local health facilities were selected for inclusion in
the trial as shown in Figure 1. The study consisted of three
phases (preparatory, implementation, and follow-up) as
shown in Figure 2.
Cluster randomization procedure
Clusters were randomized into either the intervention or
control arm following a 1:1 ratio at a public draw involv-
ing the investigator, representatives from the sponsor,
and the leaders from every cluster. Since several clusters
reported to the same local health facilities, the local
health facility was used as a stratification factor to en-
sure a balanced distribution of clusters between study
arms. Thus, seven envelopes (numbered 1 to 7) were
prepared by the trial statistician. Each contained the
name of a single local health facility and the relevant
clusters, as well as capsules each containing the name of
a single cluster. The envelopes were placed on a table
and sorted by number (number 1 on top down to num-
ber 7). Envelopes were opened sequentially from the
lowest to the highest number. When each envelope was
Figure 1 Map of the Saponé demographic surveillance system area. The control clusters are represented by circles whereas intervention
clusters are represented by squares.
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clusters were read to the audience, and all capsules from
within the envelope were placed in a transparent urn. A
representative from one of the clusters listed in the en-
velope was selected for the drawing of the capsules.
When a capsule was drawn, it was handed over to the
conductor of the session who opened it and presented
the name of the cluster it contained to the audience.
The cluster was assigned to the control or intervention
arm in an alternating fashion, i.e. the first cluster drawn
from the first envelope was assigned to the control arm,
the cluster drawn second to the intervention arm, until
the 18th cluster was drawn from the seventh envelope
and assigned to the intervention arm.
Study procedures
During the implementation phase of the study, inter-
vention and control village inhabitants participated in
three community screening campaigns that inclu-
ded home visits by mobile teams of health care
professionals. A fourth campaign was conducted afterthe rainy season had ended. This campaign marked the
end of the study at ~12 months. At these visits, finger-
prick blood samples were taken from the entire study
population in the intervention arm and a randomly
selected 40% subset of the control arm. In the interven-
tion arm, the population was screened on day 1 of
campaigns 1–3 using RDT (First ResponseW Malaria Ag,
Premier Medical Corp Ltd., Nani-Daman, India). Those
individuals with a positive test result received treatment
with AL/AL Dispersible. Subjects with positive RDT in
the intervention arm also had microscopy performed on
day 7 of campaigns 1–3 and day 28 of campaign 1. To
assess parasitological clearance, microscopy with de-
layed reading, to ensure that study personnel and
screened control subjects remained unaware of their
status, was performed on day 1 of each campaign in
both arms. Blood was also taken for Hb assessment on
day 1 and day 28 of campaign 1 and day 1 of campaign
4. Subjects with symptoms indicative of malaria were
requested to attend their local health facility for con-
firmatory testing.
Figure 2 Study design.
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were followed up for passive detection of symptomatic
malaria throughout the wet season when malaria trans-
mission is high. Participants were encouraged to report to
their local health care facility or clinic as soon as they
felt unwell. An RDT was performed for all participants
attending the local health facility with confirmed fever
(axillary temperature ≥37.5°C) or history of fever within
the last 24 hours. A blood smear was also taken. Each epi-
sode of symptomatic malaria was treated and the patient
followed up at day 7. Parasitological cure was assessed by
microscopy for each symptomaticmalaria episode on day 7.
On day 1 of campaign 4, a blood sample was also collec-
ted for gametocyte assessment by quantitative reverse
transcription-polymerase chain reaction (qRT-PCR). qRT-
PCR was conducted in 1,999 randomly selected subjects
drawn from the entire intervention group and a 40% sub-
group of the control population.
Adverse events (AEs) were collected during a period of 7
days from treatment administration, and serious adverse
events (SAEs) were recorded from the time of consent until
30 days after the subject had stopped study participation
(defined as time of last dose of investigational/alternative
treatment taken or last visit, whichever was later).
Study treatments
During the study, all individuals with a positive RDT test
in any arm, either with malaria symptoms or not,received AL/AL dispersible (20 mg artemether and
120 mg lumefantrine) twice a day for three consecutive
days. The first dose was supervised and treatment was
adjusted according to body weight: as follows: 5 to
<15 kg: 1 × AL dispersible tablet b.i.d.; 15 to <25 kg: 2 ×
AL dispersible tablets b.i.d.; 25 to <35 kg: 3 × AL tablets
b.i.d.; ≥35 kg: 4 × AL tablets b.i.d.
Any female >8 years of age with a positive RDT for
symptomatic malaria who did not take the urine preg-
nancy test or who was in the first trimester of pregnancy
received alternative treatment to AL, according to national
guidelines, as did individuals with contraindications to AL
and AL dispersible. When alternative treatment was
administered to a subject this subject had to follow the
same assessments as a subject who received AL.
Neither RDT nor treatment of asymptomatic carriers
was performed on day 1 of campaign 4, but subjects who
presented with symptomatic malaria were treated and
followed up. In cases of deterioration or severe malaria,
the patient was referred to the district hospital. Use of pre-
scription malaria treatments other than AL was tabulated
but no record was taken of any over-the-counter pur-
chases of anti-malarials.
Throughout the study, community health care workers
visited households to check and document treatment
adherence of asymptomatic carriers and those with
symptomatic malaria through the use of a drug account-
ability log and tablet counts.
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Tokyo, Japan) long-lasting, insecticide-impregnated bed
nets (LLINs), which were provided to all participants
who gave informed consent before the implementation
phase, was checked at the home visits conducted at least
every two months.
Laboratory methods
The blood films obtained during visits and for symptom-
atic malaria assessment were air-dried and Giemsa-stained
for examination. Examination was done using a light
microscope fitted with a 100 X oil immersion lens at a
single laboratory for all clusters. At least 200 thick film
fields were examined before a slide was declared negative.
If asexual forms of Plasmodia were found, a total of 200
thick film fields were screened for Plasmodium species
other than P. falciparum. When P. falciparum was pre-
sent, a count of the asexual forms against leukocytes was
made using a tally counter. Counting was done based on
at least 200 leukocytes according to the WHO standards.
If less than 10 parasites were identified from the 200
leukocyte screen, counting was extended to 1,000 leuko-
cytes. If P. falciparum gametocytes were seen, a gameto-
cyte count was performed against 1,000 leukocytes. All
slides were read by two independent microscopists. If the
ratio of densities from the first two readings was >1.5 or
<0.67 (or if less than 30 parasites were counted with an
absolute difference of more than 10 in the number of
parasites), the slide was evaluated by a third microscopist.
The definitive result was the mean of the parasite density
of the two most concordant reading results. Microscopist
competency was evaluated twice a year by proficiency
testing, in which a set of 20 slides is provided to each
microscopist for reading. Only those graded as ‘compe-
tent’, with a score of at least 80%, were involved in the
reading of slides.
qRT-PCR was performed at the Swiss Tropical and
Public Health Institute (Basel, Switzerland) using whole
blood collected from the participant’s fingertip. After
blood collection into EDTA coated microcontainer tubes,
50 μL of blood were transferred immediately into tubes
preloaded with 250 μL RNAprotect solution (Qiagen,
Valencia, CA, USA) and stored at 4°C until material was
shipped to the central genotyping laboratory. One hun-
dred and fifty μL of blood/RNAprotect solution were
processed for quantification of gametocytes using the
RNeasy Plus 96 kit (Qiagen) according to the manu-
facturer’s protocol with an additional on column step
using the RNase-free DNase Set (Qiagen). RNA was
eluted in 50 μL H20 and 2 μL were used each for qRT-
qPCR of P. falciparum A-type 18S RNA and P. falciparum
pfs25 transcripts using the TaqMan RNA-to-Ct 1-Step
Kit (Applied Biosystems, Carlsbad, CA, USA). A qPCR
was performed to demonstrate absence of genomic DNAusing the TaqMan gene expression Master Mix (Applied
Biosystems). Ct-values were converted into pfs25 templates/
μL using standard curves generated with cloned amplicons,
and subsequently transcript copy numbers were converted
into gametocytes/μL by diluting visually quantified game-
tocytes from P. falciparum strain 3D7.
Hb level was measured using the HemoCueW Hb 201+
rapid test (Ängelholm, Sweden) using blood collected by
finger-prick on day 1 and day 28 of campaign 1 and on
day 1 of campaign 4.
Statistical methods
Data analysis
Analyses in this study were focused on cluster level data
such that the cluster was considered as an experimental
unit and observations were based on individual subjects in
each cluster. The analysis was performed in two stages.
In the first stage, a summary measure was obtained for
each cluster and in the second stage a comparison was
performed based on two sets of cluster-specific measure-
ments. Cluster level data were summarized using sum-
mary statistics of cluster means for continuous variables
and cluster percentages for categorical variables. Individ-
ual level data were also reported using summary statistics
for continuous variables and number with percentage for
categorical variables [11].
One-sided t-tests of equal means for study endpoints
were conducted to a significance level of 0.05 based on
cluster-level summary data. These independently assessed
endpoints were the mean of cluster means of number of
symptomatic malaria episodes at a parasite density of
>5,000/μL per person-year in children <5 years (at day 1
in campaign 1 and in the post-campaign follow-up period)
and change in Hb level (g/dL) from day 1 to day 28 of
campaign 1 in asymptomatic carriers >6 months of age (at
day 1 and day 28 of campaign 1).
Analyses of covariance (ANCOVA) were performed for
prevalence of microscopy-confirmed gametocyte carriers
and prevalence of microscopy-confirmed asymptomatic
carriers of P. falciparum at day 1 of campaign 4. These
were assessed during the post-campaign follow-up period
(i.e. the day after day 7 of campaign 3 up to and including
the day after the last study visit. Age was considered to
be the age on day 1 of campaign 1. Cluster level preva-
lence of microscopy-confirmed asymptomatic carriage
at campaigns 2, 3 and 4 was analysed by fitting an
ANCOVA model with study arm as factor and prevalence
of asymptomatic carriers at campaign 1 as a covariate.
Prevalence of gametocyte carriage at campaigns 2, 3 and 4
was also analysed by fitting an ANCOVA model with
study arm as factor and prevalence of gametocyte carriage
at campaign 1 as covariate.
Hb levels at day 1 and day 28 of campaign 1 were
compared and age was considered to be that at the time
Table 1 Study population baseline demographics –
individual-level data
Characteristic Intervention arm Control arm
Number enrolled 6,817 7,258
Born after cluster initiation (%) 151 (2.2) 128 (1.8)
Immigrant during the study 349 (5.1) 207 (2.9)
Persons completed 5,897 (86.5) 6,510 (89.7)
Male sex (%) 46.4 47.4
Age at CSC1 day 1
Mean (years) 24.1 23.4
Age group (%)
≤6 months 2.1 1.5
>6 months to <5 years 14.9 14.2
5 to 9 years 15.8 16.6
10 to 14 years 15.5 15.3
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dren aged >6 months up to <5 years were analysed by fit-
ting an ANCOVA model with study arm as factor and
the corresponding campaign 1 summary measure as a
covariate.
Data were presented by treatment (AL/AL dispersible)
and further broken down by campaign visit. Complete
listings of medication used (AL/AL dispersible or alter-
native treatment) were generated.
All hypothesis testing was conducted one-sided at a 0.05
level of significance and all confidence intervals were
reported based on two-sided 90% confidence intervals. No
adjustments for multiplicity were performed.
Handling of missing values/censoring/discontinuations
The denominator used to calculate incidence of sympto-
matic malaria episodes at a parasite density >5,000/μL in
the cluster population was corrected for cluster subjects
who were not observed for the whole study duration (emi-
gration, immigration, birth, death, etc.). If reporting failed
at a large scale in any cluster, the cluster was to be
excluded from the incidence of symptomatic malaria ana-
lysis for evaluable clusters.
Hb level was assessed in subjects with both day 1 and
28 measurements from campaign 1. In the intervention
clusters, the initiation of treatment and the conduct of
the day-28 assessment was based on a positive RDT
result.
Ethics section
The protocol and the proposed informed consent form
were reviewed and approved by the Centre National de
Recherche et de Formation sur le Paludisme Institutional
Review Board and by the National Ethical Committee for
Health Research of Burkina Faso. Prior to study initiation,
a community meeting was held in each of the selected
clusters to discuss the study with the community. The
freedom of each individual household and a household
member to decide on participation was discussed to
minimize the potential influence of key opinion leaders in
each cluster. Individual informed consent was obtained
from each participant during a visit to the household
before any study procedure.
Results
Study demographics and baseline characteristics
A total of 6,817 persons in the intervention arm and 7,258
persons in the control arm were recruited and enrolled in
this study, as shown in Table 1. The intervention and
control arms were comparable in terms of demographic
characteristics with the exception of ethnicity; the inter-
vention arm had a higher proportion of Fulani. At the
individual level, the intervention and control arms were
comparable in terms of mean percentage of subjectscompleting the study, and were similar with respect to
births after cluster initiation (Figure 3). Immigration was
more common in the intervention arm. Discontinuation
due to death or withdrawn consent occurred at similar
rates, loss to follow up (the most common reason for
discontinuation) was slightly more common in the inter-
vention arm.
Compliance with LLIN was good at the household
checks conducted at least twice monthly, as was AL ad-
herence in those identified as asymptomatic carriers and
in individuals with symptomatic malaria.
Incidence of symptomatic malaria episodes
At 12 months, the number of RDT and microscopy-
confirmed symptomatic malaria episodes with a parasite
density >5,000/μL per person-year in infants and children
aged <5 years was not significantly different between the
intervention and control arms (1.69 [SD 0.436] vs 1.60
[SD 0.526]; p = 0.3482; Figure 4). The number of symp-
tomatic malaria episodes of any parasite density per
person-year in infants and children aged <5 years was also
not significantly different between the two arms.
Haemoglobin levels in asymptomatic carriers
Microscopy-confirmed asymptomatic carriers in interven-
tion clusters showed mean increases in Hb level compared
with the decreases seen in asymptomatic carriers in control
Figure 3 Flow chart showing numbers of participants throughout the study – trial profile.
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tically significant at the cluster level although not suffi-
ciently large to be clinically meaningful.
Incidence of asymptomatic parasitaemia and gametocyte
carriage
ANCOVA results for the prevalence of asymptomatic para-
sitaemia at the cluster level revealed lower prevalence in
the intervention arm than in the control arm at day 1 of
campaign 2 (5.0% vs 34.9%; p <0.0001) and day 1 of cam-
paign 3 (3.5% vs 31.5%; p <0.0001), but showed only a small
difference at day 1 of campaign 4 at the end of the study
(34.6% vs 37.6%; p = 0.2982; Figure 5). Mean asexual para-
site density was higher in the intervention arm than the
control arm at day 1 of campaign 3 (5,347.4/μL vs 1,062.3/μL; p = 0.0204) but not significantly different at any other
time point. Recorded mean asexual parasite densities at
any campaign ranged from 1,074/μL to 5,347/μL in the
intervention arm and 1,062/μL to 2,289/μL in the control
arm.
ANCOVA results for the prevalence of gametocyte car-
riage at the cluster level showed lower prevalence of
gametocyte carriage in the intervention arm than the con-
trol arm at day 1 of campaigns 2 and 3 (0.7% vs 5.4%;
p <0.0001 and 0.5% vs 5.8%; p <0.0001), but little differ-
ence at day 1 of campaign 4 at the end of the study (4.9%
vs 5.1%; p = 0.7208; Figure 6). Prevalence of gametocytes
at day 1 of campaign 4 as assessed by qRT-PCR was
around 8-fold greater in both arms compared with mi-
croscopy (49.7% vs 6.0% intervention; 47.3% vs 5.4%
Figure 4 Symptomatic malaria episodes with a parasite density
>5,000/μL (SMRC5000) per person-year in children
aged <5 years.
Tiono et al. Malaria Journal 2013, 12:79 Page 8 of 11
http://www.malariajournal.com/content/12/1/79control). Mean gametocyte density did not significantly
differ between the intervention and control arms at any
time point. Recorded mean gametocyte densities at any
campaign ranged from 39.2/μL to 48.6/μL in the interven-
tion arm and 21.6/μL to 49.7/μL in the control arm.
Safety evaluation
A summary of the incidence of AEs and SAEs is presented
in Table 3. Overall, there were no notable differences in
AEs or SAEs between the intervention arm and the con-
trol arm at either the cluster or individual level and no
new or unexpected safety findings were recorded. In total,
0.3% of treated asymptomatic carriers reported at least
one AE within 7 days of starting treatment. The majority
of deaths in the study occurred in subjects who had
received no study medication. Analysis of death rates in
the intervention and control arms revealed no statistically
significant differences for total deaths or deaths due to
malaria.
Discussion
In this study, community screening and targeted treat-
ment of asymptomatic carriers of P. falciparum did not
have a significant impact on the number of episodes of
symptomatic malaria with a parasite density >5,000/μL
per person-year in infants and children aged <5 years.
Although the primary end point relating to disease burdenTable 2 Cluster-level data change in haemoglobin level (g/dL
to day 28 of campaign 1 by study arm
Intervention arm
Campaign 1
Day 1 Day 28 Change
(n = 2,387) (n = 2,116)
Mean (SD) 11.81 (0.329) 12.33 (0.318) 0.53 (0.256)
n = Number of subjects from all clusters.was not met, the declines in asymptomatic parasitaemia
and gametocyte carriage in the intervention arm at day 1
of campaigns 2 and 3 show that treatment of asymptom-
atic carriers with AL did reduce the parasite reservoir.
This effect, however, was not sustained through the subse-
quent wet season to day 1 of campaign 4 and did not
translate into a reduction in symptomatic malaria episodes
in children. The observed effect therefore was not high
enough to interrupt malaria transmission. These results
do not reflect those indicated by the earlier simulation
analysis [6]. There are likely a variety of reasons for this
difference, including the dilution effect via infected vectors
from surrounding villages not involved in the study and
the high transmission intensity.
The observed levels of gametocyte carriage by micros-
copy in the intervention arm were reduced to 0.4% at day 1
of campaign 3. However, at day 1 of campaign 4 the qRT-
PCR results for gametocyte carriage revealed levels of car-
riage 8-fold greater than indicated by microscopy. These
findings suggest that by using RDT and subsequent micro-
scopic confirmation a notable proportion of gametocyte
carriers were undetected. One recent study has suggested
that significant proportions (up to 50% in low-endemic
settings) of all human-to-mosquito transmissions are
caused by submicroscopic parasite carriage [12]. If a pro-
portion of carriers were indeed not treated, this may explain
the absence of a sustained reduction in transmission seen
in this study. A study of mass drug administration with
sulphadoxine-pyrimethamine in The Gambia concluded
that only a small number of P. falciparum carriers are
required to start the next transmission season and the
results of this study support this conclusion [13]. As
discussed by Bousema and Drakely, the use of PCR to
screen the intervention population would have led to much
higher levels of asymptomatic carrier detection and subse-
quent clearance of gametocytes, perhaps to a level sufficient
to begin to impact disease transmission [14]. However, such
an intensive screening process could not be considered a
practical public health control option with the currently
available technology. RDTs likely still have a role to play in
large-scale malaria interventions. For example, they have
been used to detect local foci of asymptomatic infection in
Zambia [15]. Administration of treatment to asymptomatic
carriers surrounding index cases forms the basis of the) in asymptomatic carriers >6 months of age from day 1
Control arm p value
Campaign 1
Day 1 Day 28 Change
(n = 1,136) (n = 1,091)
12.06 (0.345) 11.86 (0.373) -0.21 (0.266) <0.0001
Figure 5 ANCOVA results for prevalence of microscopy-confirmed
asymptomatic carriers.
Figure 6 ANCOVA results for prevalence of microscopy-
confirmed gametocyte carriers.
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and elimination [16].
Overall, 96.1% of the population in the intervention
arm who consented to participation were tested by RDT.
It is unlikely that a higher level of coverage could be
achieved during a routine public health campaign. Even
if complete coverage of all inhabitants of a community
could be achieved, it is impossible to prevent the intro-
duction of disease by population migration and the
highly mobile mosquito vector. Indeed, the close prox-
imity of the intervention clusters to over 60 villages that
were not included in the study make the backflow of
infected vectors highly likely. This dilution of the inter-
vention could have been minimized by extending the
screening and treatment of asymptomatic carriers to
villages surrounding the intervention clusters, but ex-
cluding these individuals from the evaluation of the trial
end points.Table 3 Number (%) of adverse events and serious adverse in







(n = 3,819) (n = 2,554)
Abdominal pain 1 (0.03%) -
Nausea 1 (0.03%) -
Vomiting 1 (0.03%) 14 (0.5%)
Death 1 (0.03%) -
Pyrexia 1 (0.03%) -
Malaria 5 (0.1%) 2 (0.08%)
Bronchitis 2 (0.05%) -
Pneumonia 2 (0.05%) 1 (0.04%)
Respiratory tract infection 1 (0.03%) -
Dizziness 1 (0.03%) -
Asthmatic crisis 1 (0.03%) -
Somnolence - -The decrease from baseline in prevalence of asymp-
tomatic parasitaemia and gametocyte carriage between
day 1 of campaigns 1 and 4 in both the intervention and
control arm suggests a possible study effect owing to
availability of AL for all confirmed cases of malaria and
the provision of a LLIN to every participant in the study.
A recent study that examined the coverage of malaria
control interventions in Burkina Faso reported that 59%
of households in the study population owned an
insecticide-treated bed net (ITN) and only 34% of chil-
dren under 5 years of age with a reported malaria case
were treated with artemisinin-based combination ther-
apy (ACT) [17]. It is likely that receipt of a LLIN by
every study participant increased their use in both study
arms. Similarly the high level of general medical atten-
tion and easy availability of a high-quality ACT to treat
confirmed malaria cases throughout the duration of the
study could have reduced the parasite reservoir in bothartemether-lumefantrine-treated subjects















4 (0.1%) 5 (0.2%)
2 (0.05%) -
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these factors on both arms of the study would make it
more difficult to determine a benefit due to the treat-
ment of asymptomatic carriers in the intervention arm.
Another possible explanation for the lack of effect on
the incidence of symptomatic malaria with a parasite
density of >5,000/μL in children could be that the clear-
ance of asymptomatic infection increased their risk of
contracting a symptomatic infection. It has been suggested
that asymptomatic carriage might be a form of tolerance
to P. falciparum infection, which protects against the de-
velopment of clinical episodes [18]. However, it should be
noted that this is only a hypothetical explanation; the het-
erogeneity of malaria transmission, specifically variations
in local transmission intensity, may confound the data in-
dicating that clearance of asymptomatic P. falciparum in-
fection increases vulnerability to clinical episodes [19,20].
A number of studies have examined the impact of clearing
asymptomatic infections on the risk of subsequent clinical
episodes, but the data are so far inconclusive [21-24].
The second primary objective explored the impact of
treating asymptomatic carriers on Hb levels. While the
intervention resulted in a statistically significant greater
increase in Hb in asymptomatic carriers <5 years of age in
the intervention arm than in the control arm, this
improvement was not of a sufficient magnitude to be
considered clinically meaningful. As the baseline Hb level
in both populations was in the normal range, a large in-
crease in Hb could not have been expected. In 2010, a
study documented a mean Hb level of 8.7 g/dL in children
(personal communication, Dr A Tiono). However, over
the past 10 years Burkina Faso has adopted a number of
WHO-recommended interventions including the distribu-
tion of free ITNs/LLINs to vulnerable populations, and
mass administration of antihelminthic drugs [25]. The im-
pact of these interventions is likely to have improved base-
line Hb level in children in certain communities in Burkina
Faso to the point at which it is now difficult to identify fur-
ther improvement. A Cochrane Review of the impact of
ITNs concluded that sleeping under an ITN improved Hb
level in children by 1.7% packed cell volume [26].Conclusion
This study has shown that the systematic screening and
treatment of asymptomatic carriers at the community level
can reduce gametocyte carriage in a population. However,
in this setting the impact of the intervention was not
sustained. This indicates greater levels of parasite clearance
are required to interrupt transmission in this study setting.
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